205 related articles for article (PubMed ID: 28674260)
1. Relaxin Ameliorates Renal Fibrosis and Expression of Endothelial Cell Transition Markers in Rats of Isoproterenol-Induced Heart Failure.
Zheng G; Cai J; Chen X; Chen L; Ge W; Zhou X; Zhou H
Biol Pharm Bull; 2017; 40(7):960-966. PubMed ID: 28674260
[TBL] [Abstract][Full Text] [Related]
2. Relaxin inhibits cardiac fibrosis and endothelial-mesenchymal transition via the Notch pathway.
Zhou X; Chen X; Cai JJ; Chen LZ; Gong YS; Wang LX; Gao Z; Zhang HQ; Huang WJ; Zhou H
Drug Des Devel Ther; 2015; 9():4599-611. PubMed ID: 26316699
[TBL] [Abstract][Full Text] [Related]
3. Anti-Fibrosis Effect of Relaxin and Spironolactone Combined on Isoprenaline-Induced Myocardial Fibrosis in Rats via Inhibition of Endothelial-Mesenchymal Transition.
Cai J; Chen X; Chen X; Chen L; Zheng G; Zhou H; Zhou X
Cell Physiol Biochem; 2017; 41(3):1167-1178. PubMed ID: 28245473
[TBL] [Abstract][Full Text] [Related]
4. Endogenous relaxin is a naturally occurring modulator of experimental renal tubulointerstitial fibrosis.
Hewitson TD; Mookerjee I; Masterson R; Zhao C; Tregear GW; Becker GJ; Samuel CS
Endocrinology; 2007 Feb; 148(2):660-9. PubMed ID: 17095590
[TBL] [Abstract][Full Text] [Related]
5. Effect of relaxin on myocardial ischemia injury induced by isoproterenol.
Zhang J; Qi YF; Geng B; Pan CS; Zhao J; Chen L; Yang J; Chang JK; Tang CS
Peptides; 2005 Sep; 26(9):1632-9. PubMed ID: 16112403
[TBL] [Abstract][Full Text] [Related]
6. Spirolactone provides protection from renal fibrosis by inhibiting the endothelial-mesenchymal transition in isoprenaline-induced heart failure in rats.
Zhou H; Xi D; Liu J; Zhao J; Chen S; Guo Z
Drug Des Devel Ther; 2016; 10():1581-8. PubMed ID: 27217725
[TBL] [Abstract][Full Text] [Related]
7. Relaxin ameliorates salt-sensitive hypertension and renal fibrosis.
Yoshida T; Kumagai H; Suzuki A; Kobayashi N; Ohkawa S; Odamaki M; Kohsaka T; Yamamoto T; Ikegaya N
Nephrol Dial Transplant; 2012 Jun; 27(6):2190-7. PubMed ID: 22086971
[TBL] [Abstract][Full Text] [Related]
8. Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats.
Lekgabe ED; Kiriazis H; Zhao C; Xu Q; Moore XL; Su Y; Bathgate RA; Du XJ; Samuel CS
Hypertension; 2005 Aug; 46(2):412-8. PubMed ID: 15967869
[TBL] [Abstract][Full Text] [Related]
9. Relaxin ameliorates fibrosis in experimental diabetic cardiomyopathy.
Samuel CS; Hewitson TD; Zhang Y; Kelly DJ
Endocrinology; 2008 Jul; 149(7):3286-93. PubMed ID: 18388190
[TBL] [Abstract][Full Text] [Related]
10. Relaxin-1-deficient mice develop an age-related progression of renal fibrosis.
Samuel CS; Zhao C; Bond CP; Hewitson TD; Amento EP; Summers RJ
Kidney Int; 2004 Jun; 65(6):2054-64. PubMed ID: 15149318
[TBL] [Abstract][Full Text] [Related]
11. Trimetazidine Reduces Cardiac Fibrosis in Rats by Inhibiting NOX2-Mediated Endothelial-to-Mesenchymal Transition.
Chen X; Xia X; Dong T; Lin Z; Du L; Zhou H
Drug Des Devel Ther; 2022; 16():2517-2527. PubMed ID: 35946039
[TBL] [Abstract][Full Text] [Related]
12. The relaxin gene-knockout mouse: a model of progressive fibrosis.
Samuel CS; Zhao C; Bathgate RA; DU XJ; Summers RJ; Amento EP; Walker LL; McBurnie M; Zhao L; Tregear GW
Ann N Y Acad Sci; 2005 May; 1041():173-81. PubMed ID: 15956703
[TBL] [Abstract][Full Text] [Related]
13. Curcumin reduces cardiac fibrosis by inhibiting myofibroblast differentiation and decreasing transforming growth factor β1 and matrix metalloproteinase 9 / tissue inhibitor of metalloproteinase 1.
Ma J; Ma SY; Ding CH
Chin J Integr Med; 2017 May; 23(5):362-369. PubMed ID: 26956464
[TBL] [Abstract][Full Text] [Related]
14. Cinacalcet attenuates the renal endothelial-to-mesenchymal transition in rats with adenine-induced renal failure.
Wu M; Tang RN; Liu H; Xu M; Pan MM; Liu BC
Am J Physiol Renal Physiol; 2014 Jan; 306(1):F138-46. PubMed ID: 24154694
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of relaxin on cardiac fibroblast-to-myofibroblast transition: an electrophysiological study.
Squecco R; Sassoli C; Garella R; Chellini F; Idrizaj E; Nistri S; Formigli L; Bani D; Francini F
Exp Physiol; 2015 Jun; 100(6):652-66. PubMed ID: 25786395
[TBL] [Abstract][Full Text] [Related]
16. Antifibrotic properties of relaxin: in vivo mechanism of action in experimental renal tubulointerstitial fibrosis.
Hewitson TD; Ho WY; Samuel CS
Endocrinology; 2010 Oct; 151(10):4938-48. PubMed ID: 20826562
[TBL] [Abstract][Full Text] [Related]
17. SIRT1 activation attenuates cardiac fibrosis by endothelial-to-mesenchymal transition.
Liu ZH; Zhang Y; Wang X; Fan XF; Zhang Y; Li X; Gong YS; Han LP
Biomed Pharmacother; 2019 Oct; 118():109227. PubMed ID: 31351433
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of transglutaminase 2 (TG2) ameliorates ventricular fibrosis in isoproterenol-induced heart failure in rats.
Al-U'datt DGF; Tranchant CC; Alu'datt M; Abusara S; Al-Dwairi A; AlQudah M; Al-Shboul O; Hiram R; Altuntas Y; Jaradat S; Alzoubi KH
Life Sci; 2023 May; 321():121564. PubMed ID: 36931499
[TBL] [Abstract][Full Text] [Related]
19. Endogenous relaxin regulates collagen deposition in an animal model of allergic airway disease.
Mookerjee I; Solly NR; Royce SG; Tregear GW; Samuel CS; Tang ML
Endocrinology; 2006 Feb; 147(2):754-61. PubMed ID: 16254028
[TBL] [Abstract][Full Text] [Related]
20. Protective effects of relaxin against cisplatin-induced nephrotoxicity in rats.
Yoshida T; Kumagai H; Kohsaka T; Ikegaya N
Nephron Exp Nephrol; 2014; 128(1-2):9-20. PubMed ID: 25403022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
